Sponsor hub
Ipsen clinical trial failures
Review 36 stopped clinical trials from Ipsen, including disease areas, phases, and classified stop reasons.
This page groups real ClinicalTrials.gov-derived stopped trial records. The strongest added signal is the stop-reason classification: 3 of these records are likely biological failure signals, while the rest may reflect operational, strategic, regulatory, funding, enrollment, or unclear stop reasons.
Dominant stop reasons
- OPERATIONAL
- 20
- OTHER/UNKNOWN
- 13
- EFFICACY/FUTILITY
- 3
Notable sponsors
- Ipsen
- 36
Related phases
- Phase II
- 19
- Phase III
- 9
- Phase I
- 6
- Phase IV
- 2
Crawlable stopped-trial records
Open ExploreShowing up to 36 representative records from this slice. Each link opens the trial detail page with source attribution and stop-reason context.
Phase II Osteosarcoma trial by Ipsen. Stop reason: OPERATIONAL.
The sponsor has decided to terminate the CabOSTar study due to ongoing recruitment challenges
Phase IV Prostate Cancer trial by Ipsen. Stop reason: OTHER/UNKNOWN.
The study was discontinued prematurely by the sponsor due to non-medical reasons
Phase I Pancreatic Ductal Adenocarcinoma trial by Ipsen. Stop reason: OTHER/UNKNOWN.
Due to agreement to transfer rights for IPN01087 to an external partner, not due to safety concerns
Phase I Neuroendocrine Tumors trial by Ipsen. Stop reason: OTHER/UNKNOWN.
Terminated (Due to small number of ongoing patients. Patients ongoing at time of termination could choose to join study D-FR-01072-004 for long term follow-up.
Phase I Moderate Upper Facial Lines trial by Ipsen. Stop reason: OTHER/UNKNOWN.
Sponsor terminated the study due to strategic considerations
Phase II Alzheimer Disease trial by Ipsen. Stop reason: OPERATIONAL.
Inability to recruit sufficient number of patients
Phase II Insulin-like Growth Factor-1 Deficiency trial by Ipsen. Stop reason: OPERATIONAL.
The study was prematurely terminated due to strategic reasons.
Phase III Urinary Incontinence trial by Ipsen. Stop reason: OPERATIONAL.
Low recruitment of patients
Phase III Urinary Incontinence trial by Ipsen. Stop reason: OPERATIONAL.
Slow recruitment of patients
Phase III Arm Spasticity trial by Ipsen. Stop reason: OPERATIONAL.
The study was terminated early due to slow recruitment.
Phase I Small Cell Lung Cancer and Breast Cancer trial by Ipsen. Stop reason: OTHER/UNKNOWN.
High number of screen failures
Phase I Solid Tumor trial by Ipsen. Stop reason: OPERATIONAL.
Following an internal portfolio review, Ipsen has made the decision to terminate study D-US-60090-001. Ipsen would like to highlight that early termination was not due to any safety or tolerability issues with IPN60090
Phase I Pancreatic Ductal Adenocarcinoma trial by Ipsen. Stop reason: OPERATIONAL.
Business decision not related to any safety or tolerability concern
Phase III Neuroendocrine Tumors in Lung trial by Ipsen. Stop reason: OPERATIONAL.
National Comprehensive Cancer Network \& European Neuroendocrine Tumor Society guidelines (2015/2016) led to prescription of somatostatin analogues (SSAs) in this setting, thereby limiting recruitment.
Phase II Vulvodynia trial by Ipsen. Stop reason: EFFICACY/FUTILITY.
lack of efficacy
Phase III Prostatic Neoplasms, Castration-Resistant trial by Ipsen. Stop reason: OTHER/UNKNOWN.
Development of tasquinimod in prostate cancer discontinued
Phase II Carcinoid Syndrome trial by Ipsen. Stop reason: OTHER/UNKNOWN.
Preliminary data from study NCT00994214 do not support expected inhibition of GH and IGF-1
Phase II Breast Cancer trial by Ipsen. Stop reason: OPERATIONAL.
Recruitment challenges and not due to safety concerns.
Phase III Growth Disorders trial by Ipsen. Stop reason: OTHER/UNKNOWN.
Unacceptable frequency of hypoglycemia observed at and above 200 ug/kg/day
Phase II Thyroid-Associated Ophthalmopathy trial by Ipsen. Stop reason: OTHER/UNKNOWN.
No stop-reason text available in the compact dataset.
Phase III Malignant Carcinoid Syndrome trial by Ipsen. Stop reason: OTHER/UNKNOWN.
No stop-reason text available in the compact dataset.
Phase II Prostate Cancer trial by Ipsen. Stop reason: OPERATIONAL.
Low recruitment
Phase II Overactive Bladder trial by Ipsen. Stop reason: OPERATIONAL.
The study was terminated early due to poor recruitment.
Phase III Prostate Cancer trial by Ipsen. Stop reason: OPERATIONAL.
Poor enrolment
Phase III Prostate Cancer trial by Ipsen. Stop reason: OTHER/UNKNOWN.
The preliminary data do not support the expected sustainable blood levels of triptorelin for a duration of 4 months in all patients.
Phase II Acromegaly trial by Ipsen. Stop reason: OTHER/UNKNOWN.
Preliminary data from this study does not support expected inhibition of GH and IGF-1
Phase II Intestinal Obstruction trial by Ipsen. Stop reason: OPERATIONAL.
The study was terminated early due to insufficient recruitment.
Phase II Metastatic Castrate Resistant Prostate Cancer trial by Ipsen. Stop reason: OTHER/UNKNOWN.
Development of tasquinimod in prostate cancer discontinued
Phase II Prostate Cancer trial by Ipsen. Stop reason: OPERATIONAL.
Slow enrollment of patients.
Phase IV Idiopathic Short Stature trial by Ipsen. Stop reason: OPERATIONAL.
Participant enrollment was not feasible
Phase II Acromegaly trial by Ipsen. Stop reason: OPERATIONAL.
Administrative reasons
Phase II Cerebral Palsy trial by Ipsen. Stop reason: OPERATIONAL.
Low levels of recruitment
Phase II Acromegaly trial by Ipsen. Stop reason: OPERATIONAL.
Early termination is a sponsor decision. No new safety signal or serious adverse event has been observed.
Phase II Huntington's Disease trial by Ipsen. Stop reason: OPERATIONAL.
The study was terminated due to subject recruitment problems.
Phase II Endometrial Cancer trial by Ipsen. Stop reason: EFFICACY/FUTILITY.
The futility analysis of study NCT00910091 in patients with endometrial cancer shows that the primary endpoint will not be reached.
Phase II Breast Cancer trial by Ipsen. Stop reason: EFFICACY/FUTILITY.
The futility analysis of study NCT00910091 in patients with endometrial cancer shows that the primary endpoint will not be reached.